Celgene Corporation (NASDAQ:CELG)
UBS Global Healthcare Conference 2017
May 23, 2017, 01:30 PM ET
Executives
Michael Pehl - President, Global Hematology and Oncology
Terrie Curran - President, Global Inflammation and Immunology
Analysts
Carter Gould - UBS Securities LLC
Carter Gould
Great. Good afternoon everyone. My name is Carter Gould, I am the Senior Large Cap Biotech Analyst here at UBS and welcome to Day two. Next up is Celgene. Joining me on stage is Michael Pehl, President of Global Hematology and Oncology; and Terrie Curran, President of I&I. So, welcome, thank you both for joining us on stage.
I believe, to kick-off, Michael is going to make some comments to set the stage. Why [Indiscernible] and we can kind of -- [Indiscernible] the conversation.
